Ignacio F Mata

List of Publications by Year in Descending Order

86 papers	5,722 citations	33 h-index	75 g-index
95 ext. papers	6,694 ext. citations	6.6 avg, IF	4.77 L-index

#	Paper	IF	Citations
86	Looking back the importance of genetics in a patient with Parkinson disease and deep brain stimulation.. *Parkinsonism and Related Disorders*, **2022**,	3.6	
85	A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies. *Journal of Parkinson's Disease*, **2022**, 1-23	5.3	0
84	When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis. *Journal of Neurology*, **2021**, 268, 3203-3211	5.5	12
83	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. *Reviews in the Neurosciences*, **2021**, 32, 159-167	4.7	3
82	ATP1A3-Related Disorders: An Ever-Expanding Clinical Spectrum. *Frontiers in Neurology*, **2021**, 12, 637890	4.1	4
81	Characterizing the Genetic Architecture of Parkinson's Disease in Latinos. *Annals of Neurology*, **2021**, 90, 353-365	9.4	8
80	Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view. *Parkinsonism and Related Disorders*, **2021**, 88, 51-57	3.6	5
79	Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients. *Movement Disorders*, **2021**, 36, 434-441	7	4
78	Dementia in Latin America: Paving the way toward a regional action plan. *Alzheimer's and Dementia*, **2021**, 17, 295-313	1.2	26
77	Genetics of Parkinson's disease in Brazil: a systematic review of monogenic forms. *Arquivos De Neuro-Psiquiatria*, **2021**, 79, 612-623	1.6	0
76	Clinical and Genetic Analysis of Costa Rican Patients With Parkinson's Disease. *Frontiers in Neurology*, **2021**, 12, 656342	4.1	0
75	Tracing the Distribution of European Lactase Persistence Genotypes Along the Americas. *Frontiers in Genetics*, **2021**, 12, 671079	4.5	0
74	Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease. *Arquivos De Neuro-Psiquiatria*, **2020**, 78, 206-216	1.6	5
73	Novel compound heterozygous FBXO7 mutations in a family with early onset Parkinson's disease. *Parkinsonism and Related Disorders*, **2020**, 80, 142-147	3.6	2
72	Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease. *Frontiers in Neurology*, **2020**, 11, 893	4.1	1
71	Multivariate prediction of dementia in Parkinson's disease. *Npj Parkinson's Disease*, **2020**, 6, 20	9.7	10
70	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. *Neurology*, **2019**, 92, 329-337	6.5	144

69	Driving genotype treatment options down the right path(way). *Movement Disorders*, **2019**, 34, 1811-1813	7	1
68	The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru. *Parkinsonism and Related Disorders*, **2019**, 63, 204-208	3.6	20
67	Genetics of cognitive trajectory in Brazilians: 15 years of follow-up from the Bambuí Epigen Cohort Study of Aging. *Scientific Reports*, **2019**, 9, 18085	4.9	3
66	Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. *Parkinsonism and Related Disorders*, **2018**, 50, 29-36	3.6	56
65	Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease. *Nitric Oxide - Biology and Chemistry*, **2018**, 74, 86-90	5	5
64	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. *Autophagy*, **2018**, 14, 1404-1418	10.2	47
63	Intrafamilial variable phenotype including corticobasal syndrome in a family with p.P301L mutation in the MAPT gene: first report in South America. *Neurobiology of Aging*, **2017**, 53, 195.e11-195.e17	5.6	6
62	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. *Neurobiology of Aging*, **2017**, 56, 211.e1-211.e7	5.6	24
61	LARGE-PD: Examining the genetics of Parkinson's disease in Latin America. *Movement Disorders*, **2017**, 32, 1330-1331	7	19
60	Variable frequency of variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry. *Npj Parkinson's Disease*, **2017**, 3, 19	9.7	16
59	Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. *JAMA Neurology*, **2016**, 73, 1217-1224	17.2	120
58	The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2016**, 171, 925-30	3.5	11
57	GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. *Movement Disorders*, **2016**, 31, 95-102	7	113
56	Precision Medicine: Clarity for the Complexity of Dementia. *American Journal of Pathology*, **2016**, 186, 500-6	5.8	32
55	Some aspects of the validity of the Montreal Cognitive Assessment (MoCA) for evaluating cognitive impairment in Brazilian patients with Parkinson's disease. *Dementia E Neuropsychologia*, **2016**, 10, 333-338	2.1	10
54	The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. *Molecular Neurodegeneration*, **2015**, 10, 50	19	60
53	Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised. *Arquivos De Neuro-Psiquiatria*, **2015**, 73, 929-33	1.6	21
52	Cognitive profile of LRRK2-related Parkinson's disease. *Movement Disorders*, **2015**, 30, 728-33	7	42

51	A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics. *Parkinsonism and Related Disorders*, **2015**, 21, 444-8	3.6	16
50	Evaluation of mild cognitive impairment subtypes in Parkinson's disease. *Movement Disorders*, **2014**, 29, 756-64	7	48
49	Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. *Neuroscience Letters*, **2014**, 562, 45-9	3.3	23
48	Association mapping of the PARK10 region for Parkinson's disease susceptibility genes. *Parkinsonism and Related Disorders*, **2014**, 20, 93-8	3.6	13
47	Clinical and molecular studies reveal a PSEN1 mutation (L153V) in a Peruvian family with early-onset Alzheimer's disease. *Neuroscience Letters*, **2014**, 563, 140-3	3.3	5
46	Mosaicism of alpha-synuclein gene rearrangements: report of two unrelated cases of early-onset parkinsonism. *Parkinsonism and Related Disorders*, **2014**, 20, 558-61	3.6	12
45	Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease. *Neurobiology of Aging*, **2014**, 35, 2656.e17-2656.e23	5.6	17
44	The screening of the 3'UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson's disease. *Journal of Human Genetics*, **2014**, 59, 346-8	4.3	12
43	APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. *JAMA Neurology*, **2014**, 71, 1405-12	17.2	135
42	Mutational screening of PARKIN identified a 3' UTR variant (rs62637702) associated with Parkinson's disease. *Journal of Molecular Neuroscience*, **2013**, 50, 264-9	3.3	8
41	C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. *JAMA Neurology*, **2013**, 70, 742-5	17.2	18
40	Risk prediction for complex diseases: application to Parkinson disease. *Genetics in Medicine*, **2013**, 15, 361-7	8.1	10
39	APOE ε4 increases risk for dementia in pure synucleinopathies. *JAMA Neurology*, **2013**, 70, 223-8	17.2	243
38	Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). *Human Molecular Genetics*, **2013**, 22, 3259-68	5.6	89
37	Novel Lrrk2-p.S1761R mutation is not a common cause of Parkinson's disease in Spain. *Movement Disorders*, **2013**, 28, 248	7	1
36	Common variation in the LRRK2 gene is a risk factor for Parkinson's disease. *Movement Disorders*, **2012**, 27, 1822-5	7	12
35	GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. *Neurology*, **2012**, 79, 1944-50	6.5	113
34	A search for SNCA 3' UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease. *Journal of Molecular Neuroscience*, **2012**, 47, 425-30	3.3	36

33	The UCHL1 S18Y polymorphism and Parkinson's disease in a Japanese population. *Parkinsonism and Related Disorders*, **2011**, 17, 473-5	3.6	5
32	Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America. *Parkinsonism and Related Disorders*, **2011**, 17, 629-31	3.6	12
31	Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. *Movement Disorders*, **2011**, 26, 819-23	7	55
30	SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. *Archives of Neurology*, **2010**, 67, 1350-6		129
29	The genetics of Parkinson disease. *Journal of Geriatric Psychiatry and Neurology*, **2010**, 23, 228-42	3.8	214
28	Genotype-phenotype correlates in Taiwanese patients with early-onset recessive Parkinsonism. *Movement Disorders*, **2009**, 24, 104-8	7	22
27	LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease. *Movement Disorders*, **2009**, 24, 1034-41	7	48
26	GCH1 in early-onset Parkinson's disease. *Movement Disorders*, **2009**, 24, 2070-5	7	14
25	Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. *Neurogenetics*, **2009**, 10, 347-53	3	32
24	Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *New England Journal of Medicine*, **2009**, 361, 1651-61	59.2	1351
23	LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. *Parkinsonism and Related Disorders*, **2009**, 15, 370-3	3.6	28
22	Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. *Archives of Neurology*, **2008**, 65, 379-82		146
21	Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. *Annals of Neurology*, **2008**, 64, 88-92	9.4	176
20	Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. *Movement Disorders*, **2007**, 22, 389-92	7	8
19	Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. *Acta Neuropathologica*, **2007**, 113, 601-6	14.3	45
18	Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. *Parkinsonism and Related Disorders*, **2007**, 13, 509-15	3.6	39
17	LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?. *Trends in Molecular Medicine*, **2006**, 12, 76-82	11.5	78
16	Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. *Neuroscience Letters*, **2006**, 410, 80-4	3.3	46

15	Genetics of restless legs syndrome. *Parkinsonism and Related Disorders*, **2006**, 12, 1-7	3.6	8
14	LRRK2 in Parkinson's disease: protein domains and functional insights. *Trends in Neurosciences*, **2006**, 29, 286-93	13.3	390
13	LRRK2 mutations are a common cause of Parkinson's disease in Spain. *European Journal of Neurology*, **2006**, 13, 391-4	6	46
12	LRRK2 mutations and Parkinsonism. *Lancet, The*, **2005**, 365, 1229-30	40	28
11	Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. *American Journal of Human Genetics*, **2005**, 76, 672-80	11	453
10	Homozygous partial genomic triplication of the parkin gene in early-onset parkinsonism. *Neuroscience Letters*, **2005**, 380, 257-9	3.3	7
9	LRRK2 R1441G in Spanish patients with Parkinson's disease. *Neuroscience Letters*, **2005**, 382, 309-11	3.3	80
8	Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. *Parkinsonism and Related Disorders*, **2005**, 11, 349-52	3.6	26
7	Lrrk2 pathogenic substitutions in Parkinson's disease. *Neurogenetics*, **2005**, 6, 171-7	3	207
6	LRRK2 mutations in Parkinson disease. *Neurology*, **2005**, 65, 738-40	6.5	120
5	Parkin genetics: one model for Parkinson's disease. *Human Molecular Genetics*, **2004**, 13 Spec No 1, R127-33	5.3	128
4	Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. *Neuroscience Letters*, **2004**, 370, 151-4	3.3	56
3	Association between the TNFalpha-308 A/G polymorphism and the onset-age of Alzheimer disease. *American Journal of Medical Genetics Part A*, **2002**, 114, 574-7		58
2	Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease. *Neuroscience Letters*, **2002**, 329, 149-52	3.3	22
1	Characterizing the genetic architecture of Parkinson disease in Latinos		1